Calgary, Alberta – TheNewswire – December 9, 2025 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to surgeon input following first-in-human lens implantation procedures.
“The surgeon who performed our first-in-human implantations has been instrumental in shaping further improvements in the design of our lens delivery system that will be invaluable as we work to optimize the final configuration of the Ocumetics Lens,” said Dean Burns, President and CEO of Ocumetics. “Medicel’s willingness to innovate rapidly and refine their delivery platform for the Ocumetics Lens based on surgeon feedback demonstrates the strength of our partnership and Medicel’s commitment to supporting next generation accommodating intraocular lens technologies.”
The updated intraocular lens delivery system is designed to optimize loading efficiency, streamline implantation procedures, and assure its compatibility with the unique mechanical properties of the Ocumetics Lens. These improvements should allow smoother insertion and maximize surgeon acceptance of the Ocumetics Lens as the Company progresses toward expanded clinical studies.
The Company intends to use the optimized lens delivery system for its upcoming Group 2 surgeries planned for early 2026.
Forward Looking Statement Regarding Medicel
Ocumetics anticipates continued collaboration with Medicel as both companies work toward ensuring optimal delivery solutions for Ocumetics’ upcoming stages of clinical development. The Company believes that Medicel’s longstanding leadership in ophthalmic device engineering positions them as an ideal partner as Ocumetics advances toward planned regulatory engagements and expanded trials.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.
Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Dear Ocumetics Investors, I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first
Understanding the significance of the biocompatibility journey and why it’s essential for US FDA Approval Earlier this week, Ocumetics sent out a press release announcing that we completed our three-month biocompatibility study and received very favorable results. Receiving favorable results in this study is a critical aspect in the field of health care and medical
Tired of glasses? New lens technologies might offer a better way to see and experience the world. Anyone who relies on corrective eyewear has experienced its drawbacks. Maybe you are approaching your 50’s and need glasses to see up close. Maybe you left your reading glasses at home and find yourself asking for help deciphering
Ocumetics believes its accommodating lens technology could transform the eye care industry. Dr. Garth Webb, Ocumetics’ Founder and Chief Scientific Officer, thinks nothing is as beautiful as the lens in the human eye. “It’s this gorgeous, crystal-like orb that hides just behind the pupil,” he says. But it doesn’t stay that way forever. Inevitably, as
